Company profile for NurExone Biologic

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

NurExone Biologic Inc. is a TSX Venture Exchange listed pharmaceutical company that is developing a platform for biologically-guided ExoTherapy to be delivered, non-invasively, to patients who suffered traumatic spinal cord injuries. ExoTherapy was conceptually demonstrated in animal studies at the Technion, Israel Institute of Technology. NurExone is translating the treatment to humans, and the company holds an exclusive worl...
NurExone Biologic Inc. is a TSX Venture Exchange listed pharmaceutical company that is developing a platform for biologically-guided ExoTherapy to be delivered, non-invasively, to patients who suffered traumatic spinal cord injuries. ExoTherapy was conceptually demonstrated in animal studies at the Technion, Israel Institute of Technology. NurExone is translating the treatment to humans, and the company holds an exclusive worldwide license from the Technion and Tel Aviv University for the development and commercialization of the technology.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
Israel
Address
Address
9 Mezada St., BSR 3 Tower, 30 Fl., Bnei-Brak, 5120109
Telephone
Telephone
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/11/28/3196317/0/en/NurExone-Biologic-Inc-Announces-Third-Quarter-2025-Financial-Results-and-Provides-Corporate-Update.html

GLOBENEWSWIRE
28 Nov 2025

https://www.globenewswire.com/news-release/2025/11/12/3186746/0/en/NurExone-Secures-over-C-3-18-Million-Through-Accelerated-Warrant-Exercises.html

GLOBENEWSWIRE
12 Nov 2025

https://www.globenewswire.com/news-release/2025/11/03/3179779/0/en/NurExone-Accepted-into-ARMI-s-BioFab-Startup-Lab-Strengthening-U-S-Position-in-Regenerative-Manufacturing.html

GLOBENEWSWIRE
03 Nov 2025

https://www.globenewswire.com/news-release/2025/10/21/3170622/0/en/NurExone-Invited-Presenter-at-Precision-EV-Forum-in-Cambridge-UK.html

GLOBENEWSWIRE
21 Oct 2025

https://www.globenewswire.com/news-release/2025/10/08/3163347/0/en/NurExone-Demonstrates-Reproducible-Dose-Dependent-Vision-Recovery-in-Preclinical-Glaucoma-Model.html

GLOBENEWSWIRE
08 Oct 2025

https://www.globenewswire.com/news-release/2025/09/16/3151219/0/en/NurExone-Planning-to-Establish-First-U-S-Commercial-Manufacturing-Facility-in-Indiana.html

GLOBENEWSWIRE
16 Sep 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty